Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

Frank Burrell
Scientific Storytelling

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Stacey Gandler
Brand Nourishment

Liz Kane
Impactful Strategy

Paul Theisen
Patient Acquisition

Brenda Snow
Authentic Patient Voice

Matt Turner
Patient Affordability

David Linetsky
Point-of-Care Marketing

Matthew Durham
Omnidynamic Marketing

Amy Giles
Increasing Engagement